First Trust Advisors LP Cuts Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

First Trust Advisors LP lessened its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 30.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 803,666 shares of the biopharmaceutical company’s stock after selling 349,574 shares during the quarter. First Trust Advisors LP’s holdings in Alnylam Pharmaceuticals were worth $64,631,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in ALNY. Capital Investment Advisory Services LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $25,000. City Holding Co. purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $30,000. CWM LLC grew its holdings in shares of Alnylam Pharmaceuticals by 1,571.4% during the third quarter. CWM LLC now owns 585 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 550 shares during the last quarter. US Bancorp DE grew its holdings in shares of Alnylam Pharmaceuticals by 70.2% during the second quarter. US Bancorp DE now owns 628 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 259 shares during the last quarter. Finally, Price Wealth Management Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $46,000. Institutional investors and hedge funds own 93.95% of the company’s stock.

Shares of ALNY stock opened at $93.03 on Friday. The company has a current ratio of 5.38, a quick ratio of 5.22 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $10.26 billion, a P/E ratio of -12.29 and a beta of 2.37. The firm’s 50 day moving average is $84.12 and its 200 day moving average is $77.94. Alnylam Pharmaceuticals, Inc. has a 12-month low of $60.27 and a 12-month high of $96.08.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.17) by $0.25. The company had revenue of $70.06 million for the quarter, compared to the consensus estimate of $57.14 million. Alnylam Pharmaceuticals had a negative net margin of 485.73% and a negative return on equity of 52.88%. Alnylam Pharmaceuticals’s revenue for the quarter was up 3284.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.56) EPS. As a group, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -7.89 earnings per share for the current year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

ALNY has been the topic of a number of recent analyst reports. Zacks Investment Research cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $93.00 price target on the stock. in a report on Wednesday, September 18th. Morgan Stanley cut their price target on shares of Alnylam Pharmaceuticals from $126.00 to $124.00 and set an “overweight” rating on the stock in a report on Wednesday, August 7th. ValuEngine cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday. Cowen cut their price target on shares of Alnylam Pharmaceuticals from $147.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Finally, BidaskClub cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $111.59.

In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 58,913 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $89.99, for a total value of $5,301,580.87. Following the sale, the president now directly owns 111,851 shares in the company, valued at approximately $10,065,471.49. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO John Maraganore sold 49,456 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, October 14th. The shares were sold at an average price of $79.45, for a total transaction of $3,929,279.20. Following the completion of the sale, the chief executive officer now owns 239,449 shares in the company, valued at $19,024,223.05. The disclosure for this sale can be found here. Insiders own 3.60% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Read More: How is a price target determined?

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Leave a Reply

Your email address will not be published. Required fields are marked *

*